Bone mesenchymal stem cells differentiate into myofibroblasts in the tumor microenvironment

Area of Science:

• Cell Biology
• Oncology
• Regenerative Medicine

Background:

• Mesenchymal stem cells (MSCs) are known for their immunomodulatory and regenerative properties.
• The tumor microenvironment (TME) is a complex ecosystem that influences tumor progression.
• Understanding MSC behavior within the TME is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the tropism of mesenchymal stem cells (MSCs) towards the tumor microenvironment (TME).
• To evaluate the potential of bone marrow-derived MSCs to differentiate into myofibroblasts in vitro.
• To explore the implications of MSC differentiation in the TME for tumor growth.

Main Methods:

• Isolation and culture of bone marrow mesenchymal stem cells (MSCs) from New Zealand rabbits.
• Characterization of MSCs using flow cytometry for surface markers (CD44+, CD105+, CD106+, CD34-).
• VX2 tumor model utilized for conditioned medium preparation and Transwell migration assays to assess MSC tropism.
• Analysis of α-smooth muscle actin (α-SMA) and vimentin expression via RT-PCR and Western blotting to evaluate myofibroblast differentiation.

Main Results:

• MSCs exhibited significant migration towards VX2 tumor-conditioned medium in Transwell assays.
• Incubation with tumor-conditioned medium led to a significant increase in mRNA and protein expression of α-SMA and vimentin in MSCs.
• These changes indicate a differentiation of MSCs into myofibroblast-like cells in vitro.

Conclusions:

• MSCs demonstrate tropism for the tumor microenvironment.
• Bone marrow-derived MSCs can differentiate into myofibroblasts in vitro when exposed to the TME.
• This differentiation may contribute to tumor progression and suggests MSCs as potential precursors for tumor-associated myofibroblasts.